GlassScriptPhysician profile
Julie E Bradford
NPI 1467796417
$1,889.00
in general payments reported to CMS, 2019-2025
31 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $528 · 2023: $408 · 2024: $293 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.44 | 2021-2025 | |
| Novo Nordisk INC | $331.84 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $126.99 | 2021-2025 | |
| Lilly USA, LLC | $96.44 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $81.74 | 2022-2024 | Verquvo, Gardasil 9, Steglatro |
| Dexcom, INC. | $66.87 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.05 | 2021-2025 | |
| Glaxosmithkline, LLC. | $55.58 | 2023-2025 | Shingrix, Bexsero, Pediarix |
| Exact Sciences Corporation | $50.71 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $44.73 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $43.94 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $35.43 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $33.75 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $33.49 | 2022-2023 | |
| Amarin Pharma, INC. | $29.15 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.38 | 2022-2025 | Jardiance |
| Amryt Pharma Holdings LTD | $27.14 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $23.57 | 2024 | Voxzogo 1.2mg |
| Averitas Pharma INC. | $20.81 | 2023 | Qutenza |
| Eisai INC. | $18.65 | 2024 | |
| Dynavax Technologies Corporation | $18.41 | 2022 | |
| Ibsa Pharma INC. | $18.24 | 2023 | Tirosint, Licart |
| Idorsia Pharmaceuticals US INC | $17.81 | 2023 | Quviviq |
| Organon LLC | $17.63 | 2025 | Nexplanon |
| Esperion Therapeutics, INC. | $16.57 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.65 | 2023 | Austedo |
| E.R. Squibb & Sons, L.L.C. | $15.60 | 2023 | Eliquis |
| Antares Pharma, INC. | $15.56 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.25 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.84 | 2021 | |
| Cranial Technologies, INC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Bradford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.